Related Experiment Video
Updated: May 25, 2025
Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells
Published on: May 2, 2017
Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted
Qian Chen1, Tong Yu1, Jingyi Gong1
1Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA, Institute for Frontier Medical Technology, College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
Insights
Advanced drug delivery systems offer improved cardiovascular disease (CVD) treatment by enhancing drug targeting and efficacy. This review explores novel materials and vectors, aiming to improve patient outcomes for cardiovascular diseases.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Cardiology
Background:
- Cardiovascular diseases (CVDs) are a major global health concern with limitations in current treatments.
- Conventional therapies for CVDs face challenges including poor targeting, reduced efficacy, and adverse effects.
- There is a critical need for advanced therapeutic strategies to improve CVD management.
Purpose of the Study:
- To review and categorize novel drug delivery materials for cardiovascular diseases (CVDs).
- To evaluate the efficacy and feasibility of viral and non-viral vectors in CVD treatment.
- To discuss limitations and future prospects of advanced drug delivery systems for CVDs.
Main Methods:
- Comprehensive literature review of drug delivery systems for CVDs.
- Classification of various drug delivery materials based on targeting and efficacy.
- Evaluation of viral and non-viral vectors for pharmaceutical delivery in cardiovascular applications.
Main Results:
- Identified advanced drug delivery systems with high specificity, biodegradability, and biocompatibility.
- Drug delivery systems demonstrate enhanced therapeutic outcomes through precise delivery and high drug-loading.
- Viral and non-viral vectors show potential for targeted CVD treatment, though challenges remain.
Conclusions:
- Advanced drug delivery systems offer significant advantages over conventional CVD therapies.
- Novel materials and vectors are crucial for improving the precision and efficacy of CVD treatments.
- Further research into drug delivery systems holds promise for enhanced patient care in cardiovascular diseases.
Abstract:
Cardiovascular diseases (CVDs) represent a leading global health crisis, significantly impairing patients' quality of life and posing substantial risks to their survival. Conventional therapies for CVDs often grapple with challenges such as inadequate targeting precision, suboptimal therapeutic efficacy, and potential adverse side effects. To address these shortcomings, researchers are intensively developing advanced drug delivery systems characterized by high specificity and selectivity, excellent biodegradability, superior biocompatibility, and minimal toxicity. These innovative systems enable the precise delivery of pharmaceuticals with high drug-loading capacities, minimal leakage, and expansive specific surface areas, thereby enhancing therapeutic outcomes. In this review, we summarize and classify various drug delivery materials targeting CVDs and application values. We also evaluate the feasibility and efficacy of viral and non-viral vectors for the treatment of CVDs, the existing limitations and application prospects are also discussed. We hope that this review will provide new perspectives for the future development of drug delivery systems for the treatment of CVDs, ultimately contributing to improved patient care and outcomes.
